Morgan Stanley says that Planned Parenthood funding freeze is weighing on Cooper Companie’s stock due to worries on its CSI business. The firm believes the impact is likely very modest, maybe $15M for Paragard on Morgan Stanley’s math given small implant numbers. Patients are also likely to shift to other channels, while increase in births partly offsets impact, it adds. Overall, the firm sees likely very limited impact for Cooper. Morgan Stanley has an Equal Weight rating on the shares with a price target of $92.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COO:
- Hold Rating for Cooper Co Amid Minimal Impact from Planned Parenthood Funding Cuts
- Cooper Companies management to meet with Piper Sandler
- Cooper Co: A Compelling Buy Amid Market Uncertainties and Attractive Valuation
- Cooper Companies price target lowered to $92 from $102 at Morgan Stanley
- Cooper Companies’ Earnings Call Highlights Robust Growth